Divisas / NVAX
NVAX: Novavax Inc
6.67
USD
0.34
(4.85%)
El tipo de cambio de NVAX de hoy ha cambiado un -4.85%. En este caso, el precio mínimo en el mercado ha alcanzado 6.12, mientras que el máximo ha alcanzado 7.16.
Siga la dinámica de la pareja de divisas Novavax Inc. El gráfico histórico le mostrará cómo ha cambiado el precio de %AssetName% en el pasado. Alternando entre diferentes marcos temporales, podrá monitorear las tendencias y la dinámica del tipo de cambio por minutos, horas, días, semanas y meses. Use esta información para predecir los cambios en el mercado y tomar decisiones comerciales fundamentadas.
- M5
- M15
- M30
- H1
- H4
- D1
- W1
- MN
NVAX News
- Investing Novavax shares fall following WSJ report on FDA trial request
- Investing As FDA delays Novavax’ COVID vaccine approval, patients fight back
- GuruFocus Novavax Shares Surge 17% as FDA Requests Postmarketing Data for COVID-19 Vaccine
- Benzinga Amphenol Posts Better-Than-Expected Results, Joins SAP, Tesla, Pegasystems And Other Big Stocks Moving Higher On Wednesday - Amer Sports (NYSE:AS), Amphenol (NYSE:APH)
- Investing FDA asks Novavax for commitment on post-approval studies for COVID vaccine
- Investing Moderna, Novavax shares dip as CDC panel suggests limiting COVID shot updates
- Benzinga Novavax Covid Vaccine Shows Milder Side Effects Than Pfizer-BioNTech's Shot: Study - Novavax (NASDAQ:NVAX)
- Investing Analysis-Trump health policy uncertainty sends biotech sector into deeper slump
- Seeking Alpha Novavax: Regulatory Uncertainty Creates Risk And Opportunity
- Investing Novavax shares tumble after U.S. health secretary raises concerns over COVID shot’s efficacy
- Investor Place Sell or Buy? Here’s What Louis Is Doing After “Liberation Day”
- Benzinga Despite Headwinds, Biotech Sell-Off Could Offer Buying Opportunity: Analyst - Novavax (NASDAQ:NVAX), Sanofi (NASDAQ:SNY)
- Benzinga FDA Delays Full Approval Decision On Novavax's COVID-19 Vaccine (UPDATED) - Novavax (NASDAQ:NVAX)
- Benzinga FDA Delays Full Approval Decision On Novavax's COVID-19 Vaccine - Novavax (NASDAQ:NVAX)
- Investing FDA misses deadline for decision on Novavax’s COVID-19 vaccine, source says
- MarketWatch In a rare move, Wall Street analysts get pointed in their criticism of RFK Jr.
- Seeking Alpha FDA Shake-Up Rocks Moderna Stock As Regulatory Risks Mount (Downgrade) (MRNA)
- Benzinga Moderna, Novavax Shares Are Tumbling Monday: What's Going On? - Moderna (NASDAQ:MRNA)
- Investing Pharma stocks sink after ouster of top FDA vaccine regulator
- Seeking Alpha AbbVie Vs. Sanofi: Which Is The Better Investment Right Now (NYSE:ABBV)
- Benzinga Moderna, Novavax Shares Are Sliding Wednesday: What's Going On? - Moderna (NASDAQ:MRNA)
- Investing Factbox-Widely used drugs on US imports list from Europe
- The Motley Fool 2 Beaten-Down Stocks Near Their 52-Week Lows That Aren't Worth Buying
- Seeking Alpha Novavax, Inc. (NVAX) Leerink Partners 2025 Global Healthcare Conference (Transcript)
Rango diario
6.12
7.16
Rango anual
4.29
23.86
- Cierres anteriores
- 7.07
- Open
- 7.01
- Bid
- 6.67
- Ask
- 6.97
- Low
- 6.12
- High
- 7.16
- Volumen
- 21.673 K
- Cambio diario
- -4.85%
- Cambio mensual
- 4.06%
- Cambio a 6 meses
- -31.45%
- Cambio anual
- 55.48%
26 abril, sábado
00:00
ALL
- Act.
- Pronós.
- Prev.